Sfoglia per AUTORE
GALLI L
Collezione AOU Novara

  

Items : 10

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? in European urology oncology / Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.

2024
ASL Cuneo 2
AOU Novara

Porta C; Battelli N; Bracarda S; Sorgentoni G; Monteiro FSM; Mollica V; Rizzo A; Zabalza IO; Bimbatti D; Soares A; Bisonni R; Rebuzzi SE; Roviello G; Incorvaia L; Morelli F; Santini D; Vau N; Bhuva D; Küronya Z; Mosca A; Landmesser J; Milella M; Messina C; Bassanelli M; Ortega C; Grillone F; Procopio G; Sunela K; Caffo O; et alii...

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep

2023
ASL Cuneo 2
AOU Novara

Santoni M; Porta C; Bellmunt J; Battelli N; Sorgentoni G; Landmesser J; Rizzo A; Mollica V; Zabalza IO; Zgura A; Incorvaia L; Ansari J; Pinto A; Soares A; Nunes F; Maluf F; Morelli F; Mosca A; Zakopoulou R; Bisonni R; Manneh R; Santini D; Inman E; Herchenhorn D; Kanesvaran R; Caitano M; Milella M; Kopecky J; Martignetti A; et alii...

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. in Targeted oncology / Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27.

2023
AOU Novara

Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; et alii...

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. in Minerva urology and nephrology / Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7.

2023
AO Cuneo
ASL Cuneo 2
AOU Novara

Grande E; Santoni M; Buti S; Battelli N; Sorgentoni G; Pierantoni F; Monteiro FS; Rebuzzi SE; Roviello G; Soares A; Zabalza IO; Rizzo A; Bisonni R; Morelli F; Incorvaia L; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Messina C; Merler S; Landmesser J; Grillone F; Ortega C; Sunela K; Ansari J; Atzori F; Bassanelli M; et alii...

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. in Therapeutic advances in urology / Ther Adv Urol. 2021 Oct 22;13:17562872211054302. doi: 10.1177/17562872211054302. eCollection 2021 Ja

2021
ASL Vercelli
AOU Novara

La Torre L; Baldessari C; Gernone A; Dalla Volta A; Toscani I; Zucali PA; Corti F; Fanelli M; Stellato M; Morelli F; Mucciarini C; Galli L; Macrini S; Atzori F; Gatti A; Caffo O; Fornarini G; Vitale MG; Massari F; Masini C; Cattrini C; Cortellini A; Rizzo M; Buti S; Bersanelli M; Zara D; Gennari A; Bracarda S; Procopio G; et alii...

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases / Clin Microbiol Infect. 2019 Nov;25(11):1443-1446. doi: 10.1016/j.cmi.2019.07.004. Epub 2019 Jul 25.

2019
ASL Città di Torino
ASL VCO
AOU Novara

Di Biagio A; Bonora S; Monno L; Paolini E; Callegaro AP; Zoncada A; Pecorari M; Francisci D; Borghi V; Galli L; Vicenti I; Bruzzone B; Taramasso L; Ungaro R;

The effect of a treatment delay on outcome in metastatic renal cell carcinoma. in Urologic oncology / Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29.

2019
AOU Novara

Iacovelli R; Galli L; De Giorgi U; Porta C; Nolè F; Zucali P; Sabbatini R; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Buti S; Massari F; Masini C; Ricotta R; Biasco E; Lolli C; Gri N; Verri E; Miggiano C; Vitale MG; Tortora G;

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7.

2018
AOU Novara

Iacovelli R; De Giorgi U; Galli L; Zucali P; Nolè F; Sabbatini R; Fraccon AP; Basso U; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Pasini F; Masini C; Massari F; Buti S; Sava T; Sacco C; Ricotta R; Sperduti I; Tortora G; Porta C;

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. in Anticancer research / Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807.

2018
AOU Novara

Sbrana A; Biasco E; Paolieri F; Palesandro E; Caserta C; Iacovelli R; Detti B; Santini D; Mosca A; Morelli F; Fornarini G; De Giorgi U; Masini C; Galli L;

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. in Urologic oncology / Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

2017
AOU Novara

Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G;